(Reuters) – Novavax Inc said on Thursday South Korea’s SK bioscience will manufacture a component of the U.S. drug developer’s experimental coronavirus vaccine.
In addition, the companies said they had signed a letter of intent with the Republic of Korea’s Ministry of Health and Welfare to make the vaccine available in South Korea.
(Reporting by Manas Mishra in Bengaluru; Editibg by Krishna Chandra Eluri)
